Compare MobilEye Global Inc (MBLY) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MobilEye Global Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? MobilEye Global Inc trades at $7.07 (market cap $6.08B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 21.1× MobilEye Global Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, MobilEye Global Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold MobilEye Global Inc for 15 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| MBLY | VRTX | |
|---|---|---|
Market Cap | $6.08B | $128.16B |
Volume | 4,250,290 | 806,603 |
Sector | Consumer Cyclical | Health |
52-Week High | $15.42 | $557.96 |
52-Week Low | $6.56 | $407.37 |
Typical Hold Time | 15 Days | 120 Days |
Enterprise Value | $4.64B | $122.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mobileye Global (MBLY) trades at $7.15, down 4.28% amid bearish technical signals, though RSI levels suggest potential oversold conditions. The company shows mixed fundamentals with strong revenue growth to $2.0B in 2026 but deep losses (-$4.1B net income). Analyst consensus remains positive with 57.7% buy ratings and $10.83 price target, while recent news highlights ADAS business momentum and autonomous vehicle expansion initiatives.
MBLY presents a high-risk opportunity with significant upside potential if execution improves, but current profitability challenges and bearish technicals warrant caution. The stock trades below book value (P/B 0.74) with institutional confidence shown through recent insider buying, though competitive pressures in autonomous driving and ongoing losses represent substantial investor risks.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% on the day, with a bearish technical signal despite a neutral oscillator reading. The company reported strong 2025 revenue of $12.00B and net income of $3.95B, with a net margin of 35%. Recent positive Phase 2b data for its kidney disease drug inaxaplin highlights pipeline expansion beyond cystic fibrosis dominance. Analyst consensus is strongly bullish with an 83.9% buy rating and a $573.50 price target, implying 13.4% upside.
The outlook for VRTX is positive, driven by its profitable core business and promising pipeline, but faces risks from clinical trial outcomes and competitive pressures. The stock's current valuation at a P/E of 29.45 is reasonable given its growth prospects, though investors should monitor execution on new drug approvals and market adoption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About MobilEye Global Inc
Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.
Read more on MBLY →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
